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The readthrough of nonsense mutations by small molecules like Ataluren is considered a novel therapeutic
approach to overcome the gene defect in several genetic diseases as cystic fibrosis (CF). This pharmacological
approach suppresses translation termination at premature termination codons (PTCs readthrough) thus restoring
the expression of a functional protein. However, readthrough might be limited by the nonsense-mediated mRNA
decay (NMD), a cell process that reduces the amount/level of PTCs containing mRNAs. Here we investigate the
combined action of Ataluren and caffeine to enhance the readthrough of PTCs. IB3.1 CF cells with a nonsense
mutation were treated with caffeine to attenuate the Nonsense-Mediated mRNA Decay (NMD) activity and thus
enhance the stability of the nonsense (ns)-CFTR-mRNA to be targeted by Ataluren. Our results show that NMD
attenuation by caffeine enhances mRNA stability and more importantly when combined with Ataluren increase
the recovery of the full-length CFTR protein.1. Introduction
Nonsense mutations are responsible up to 70% of the individual cases
of most inherited diseases, including cystic fibrosis (CF), Duchenne
muscular dystrophy (DMD) and a variety of other genetic disorders and
cancer (Baker and Parker, 2004; Maquat, 2005). Besides gene therapy,
pharmacological approaches aiming at modifying gene expression by
promoting the ribosomal readthrough of nonsense mutations have
gained interest in these years (Rowe and Clancy, 2009; Goldmann et al.,
2012; Lentini et al., 2014; Pibiri et al., 2015; Roy et al., 2016; Dabrowski
et al., 2018; Tutone et al., 2019).
Cystic fibrosis (CF) is caused by mutations in the gene encoding the
cystic fibrosis transmembrane conductance regulator (CFTR). So far, 27
different nonsense mutations, corresponding to 10% of cystic fibrosis
(CF) cases worldwide have been identified (Kerem et al., 2008).
A potential treatment for these patients makes use of drugs that
selectively suppress translation termination at in-frame premature
termination codons (PTCs). Among these aminoglycosides were previ-
ously employed to suppress the normal proof-reading function of the
ribosome (Prayle and Smyth, 2010) leading to the insertion of a
near-cognate amino acid at the PTC site, thus allowing the translation of a
full-length protein. This "translational readthrough" of premature stopini), aldo.dileonardo@unipa.it (A
31 May 2019; Accepted 12 June
is an open access article under tcodons has been shown to partially restore protein function in a number
of preclinical settings (Goldmann et al., 2012; Harmer et al., 2012;
McElroy et al., 2013, Aslam et al., 2017). However, severe side-effects
caused by prolonged treatments with aminoglycosides have been re-
ported limiting their widespread clinical use for this purpose (Sarkar
et al., 2011; Wilschanski et al., 2011; Kerem et al., 2014).
On the contrary, the compound PTC124 (Ataluren) reported to pro-
mote the readthrough of premature but not normal termination codons
does not possess the toxicity of aminoglycosides and has been suggested
as a potential treatment for genetic disorders caused by nonsense mu-
tations, particularly those involving the UGA premature codon (Welch
et al., 2007; Lentini et al., 2014, Lentini et al., 2015).
Although some studies (Auld et al., 2009; McElroy et al., 2013; Kerem
et al., 2014) questioned whether Ataluren is able to promote read-
through, several independent publications demonstrated its efficacy
(Goldmann et al., 2012; Lentini et al., 2014; Pibiri et al., 2015, 2016,
2018; Roy et al., 2016). Moreover, Ataluren clinical trials showed the
efficacy in the readthrough of premature stop codon (Wilschanski et al.,
2011; Finkel et al., 2013; Ng et al., 2018). However, the amount of
readthrough can be limited by the nonsense-mediated mRNA decay
(NMD) pathway, a conserved eukaryotic cellular pathway that targets
PTC-containing mRNAs for degradation (Keeling et al., 2013; Linde et al.,. Di Leonardo).
2019
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
L. Lentini et al. Heliyon 5 (2019) e019632007). Several drugs such as SMG1 kinase inhibitors have been found to
attenuate the NMD pathway by inhibiting the Upf1 and the Upf1 protein
phosphorylation (Keeling, 2016). Caffeine attenuate NMD by blocking
the UPF1 phosphorylation cycle by inhibiting the SMG1 kinase that
phosphorylates UPF1 (Keeling et al., 2013). Inhibition of NMD may
enhance the effect of nonsense suppression drugs to restore protein
function by increasing steady-state mRNA abundance (Keeling et al.,
2013).
Here we report new evidences about the enhancement of premature
stop codon readthrough of the CFTR mRNA by Ataluren when associated
with caffeine an inhibitor/attenuator of the NMD response providing
new insights for Ataluren therapeutic improvement.
2. Materials and methods
2.1. Cell culture conditions and caffeine/PTC124 treatment
The IB3.1 cell line, gifted by Dr. Paola Melotti, Azienda Ospedaliera
Universitaria Integrata, Verona, Italy, is a bronchial cell line derived from
a cystic fibrosis patient with a ΔF508/W1282X CFTR genotype. IB3.1
cells were cultured in DMEM supplemented with FBS 10% (GIBCO) in a
humidified atmosphere of 5% CO2 in air at 37 C. Caffeine treatment was
performed for 24h at different concentrations (0.75, 1.5, 3 mM), while
Ataluren/PTC124 and G418 were added in the cell medium for 24 or 72
hours at 12 μМ and 430 μM, respectively.
2.2. Trypan blue dye exclusion cell viability test
The number of dead (blue stained) and live (clear cytoplasm) cells
after caffeine treatment was quantified using trypan blue staining. The
cells were detached from the plate surface and then diluted in 0.4%
trypan blue stain (v:v) (Gibco by Life Technologies) and counted in a
Burker chamber. The percentage of viable cells was calculated by
dividing the number of live cells by the total number of cells, multiplied
by 100. Three replicates were performed for each condition.
2.3. Immunofluorescence microscopy
To visualize the CFTR protein cells were grown on rounded glass
coverslips and fixed with cold methanol for 2 min. The cell membrane
and Golgi apparatus were stained by the Wheat Germ Agglutinin (WGA)
Alexa 594 1:1000 (Life Technologies). For CFTR-detection cells were
blocked with 0.1% BSA (60 min) at RT and cover slips were incubated
with a mouse monoclonal antibody against the first extracellular loop of
human CFTR (Abcam, 1:500) overnight at 4 C, followed by a goat
polyclonal to mouse Alexa-Fluor-488 (Abcam, 1:1000) secondary anti-
bodies for 1h at 37 C. Nuclei were visualized with DAPI. Cells were
examined under a Zeiss Axioskop microscope equipped for fluorescence.
2.4. Real-time RT-PCR
Primers used in real-time RT-PCR experiments were designed withFig. 1. CFTR mRNA was increased in IB3.1 cells treated with PTC124 (Ataluren). Rea
(G418 and PTC124) for 24 hours.
2Primer Express software (Applied Biosystems, Monza, Italy) or based on
Kerem et al., (2008) (5). Amplicons size was of approximately
70–100 bp. When not already tested the selected sequences were blasted
against public databases using BLAST to confirm the identity of the
genes. Total RNA was extracted from cells by using the RNAeasy Mini kit
according to manufacturer's instruction (Qiagen, Milano, Italy). RNA was
reverse-transcribed in a final volume of 50 μl using the High Capacity
cDNA Archive kit (Applied Biosystems, Monza, Italy) for 10 min at 25 C
and 2 h at 37 C. For each sample 2 μl of cDNA, corresponding to 100 ng
of reverse transcribed RNA, was analyzed by real-time RT-PCR (95 C for
15 s, 60 C for 60 s repeated for 40 cycles), in quadruplicate, using the
ABI PRISM 7300 instrument (Applied Biosystems, Monza, Italy).
Real-Time RT-PCR was done in a final volume of 20 μl comprising 1x
Master Mix SYBR Green (Applied Biosystems, Monza, Italy) and 0.3μM of
forward and reverse primers for: CFTR (Fwd: 50-CTACATGGAACACA-
TACCTTCG-3'; Rev: 50-GGTGATAATCACTGCATAGC-30) (29);
non F508del-CFTR (Fwd: 50-GCACCATTAAAGAAAATATCATCTT-3;
Rev:50-TTGTCTTTCTCTGCAAACTTGG-30) (Kerem et al., 2008),
GAPDH (Fwd: 50-CTCATGACCACAGTCCATGCC-30; Rev:
;50-GCCAATCCACAGTCTTCTGGGT-30). Data were analyzed by aver-
aging quadruplicates Ct (cycle threshold). Levels of RNA were deter-
mined by using the SDS software version (Applied Biosystems, Monza,
Italy) according to the 2ΔΔCt method and Ct values were normalized to
the internal control GAPDH.2.5. Western blotting
Proteins (50 μg) were separated by 3–8% SDS-PAGE (Bolt, Life
Technologies) containing 0.1% SDS and transferred to Hybond-C nitro-
cellulose membranes (Amersham Life Science) by electroblotting. For
CFTR detection the membrane was incubated with a goat polyclonal
anti–CFTR antibody (C-19, Santa Cruz 1:500) raised against a peptide
mapping near the C-terminus of human CFTR, and HRP-conjugated anti-
goat (Abcam, 1:5000). The target protein was detected by ECL reagent
(Pierce). We used an anti-β-tubulin antibody (mouse; Sigma-Aldrich
1:10.000) to confirm equal proteins loading. Gel bands were quantified
by Image Lab software (BioRad). WB assays were repeated at least three
times and were reproducible within 5 % variations.
3. Results
3.1. Prolonged treatment with Ataluren increases the CFTR-transcript
It has been reported that different readthrough-promoting RNA
compounds have similar capacities to inhibit the nonsense-mediated
mRNA decay (NMD) pathway and that the level of translational read-
through required to skip NMD depends on how distant is the PTC from
the end of the mRNA (Baker and Hogg, 2017; Midgley, 2019). We used
the IB3.1 cells to investigate if Ataluren (indicated as PTC124 in figures)
is able to stabilize the mRNA containing nonsense mutations in addition
to the suggested readthrough activity. Cells were treated also with G418
as a control since it affects mRNA stabilization of genes containing PTCsl-Time RT-PCR of CFTR, RB and actin genes in IB3.1 cells treated or left untreated
Fig. 3. Cell viability of IB3.1 cells after caffeine treatment. A) Graph shows the num
cells untreated or treated with 0.75–1.5–3 mM caffeine for 24 hours.
Fig. 2. The increase of CFTR mRNA level after treatment of IB3.1 cells with
Ataluren/PTC124 was specific for the nonsense mutated mRNA. Real-Time RT-
PCR with primers specific for the nsCFTR-mRNA after 24 hours of treatment
with G418 and PTC124.
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3(Salvatori et al., 2009). Real-Time RT-PCR showed that G418 and Ata-
luren increased 5 folds and 3 folds the CFTR transcript, respectively
(Fig. 1). To exclude a general effect on mRNA stabilization caused by
G418 and Ataluren we looked at the expression levels of two unrelated
genes: RB (Retinoblastoma) and ACTB (β-actin). Real-Time RT-PCR did
not show an increase of RB and ACTB mRNAs, indicating that the mRNA
stabilization was specific for the CFTR transcript with PTC (Fig. 1).
To exclude that the observed increase of the CFTR mRNA was
attributable to the ΔF508-CFTR allele we used two primers specifically
designed to amplify only the not-ΔF508 CFTR transcripts (Kerem et al.,
2008). The Real-Time RT-PCR done with these primers (Fig. 2) shows
that after the treatment with G418 and PTC124 (Ataluren) the IB3.1 cells
still show increased levels of the CFTR mRNA (mainly nonsense CFTR
mRNA) confirming the results of the previous analysis.3.2. Low doses of caffeine do not affect cell viability and stabilize the
nsCFTR mRNA
Ataluren might increase the nonsense CFTR transcript by impairing
the nonsense-mediated mRNA decay (NMD) pathway. This surveillanceber of live or dead cells after 24 hours of caffeine treatment. B) Images of IB3.1
Fig. 4. Caffeine treatment increases CFTR mRNA levels in IB3.1 cells. Real-Time
RT-PCR shows increased levels of the CFTR mRNA after 24 hours treatment with
0.75mM caffeine.
L. Lentini et al. Heliyon 5 (2019) e01963system degrading the mRNA harboring PTCs clearly disadvantages Ata-
luren's readthrough (Keeling et al., 2013). Thus, we hypothesized that
the use of caffeine hampering the NMD (Shi et al., 2008) might increase
the mutated (nonsense) CFTR mRNA boosting Ataluren readthrough ef-
fect. To this aim, the IB3.1 cells were treated with caffeine and Ataluren
separately or in combination and the levels of the CFTR mRNA and
protein were evaluated.
Caffeine has been reported to cause a different degree of toxicity
according to the cell type used (Shi et al., 2008). We performed then a
cell viability assay in order to choose the optimal dose of caffeine that
allows the IB3.1 cells to survive to the treatment. To this aim, cells were
treated for 24 hours with different concentrations (0.75–1.5 and 3 mM).
We observed that 0.75 mM of caffeine treatment did not affect signifi-
cantly cells viability and cell morphology (Fig. 3-A, B) and this concen-
tration was used for further experiments.
We evaluated then the CFTR mRNA levels by Real-Time RT-PCR after
treatment with 0.75 mM of caffeine. The analysis revealed a 1.5 fold
change of the CFTR mRNA compared to the untreated cells (Fig. 4).
3.3. Combined effect of Ataluren and caffeine induced CFTR protein
expression in cystic fibrosis cells
To favor the increase of the CFTR mRNA levels in the attempt to
enrich the target for the Ataluren mediated readthrough, we performed a
combined treatment of the two molecules: caffeine and Ataluren. IB3.1
cells were treated with 0.75 mM caffeine for 24 hours, the medium was
then changed and Ataluren was added at the concentration of 12 μM for
additional 24 hours.
Real-Time RT-PCR analysis in IB3.1 cells confirmed the partial CFTR
mRNA increase/stabilization after caffeine (1.5 folds) and Ataluren (2.5
folds) treatment in comparison to to untreated control cells (Fig. 5-A).
Moreover, the Real-Time RT-PCR analysis showed the additive effect on
the CFTR mRNA level following the caffeine and Ataluren combined4treatment (3.8 folds) (Fig. 5-A).
As expected the increase in the nonsense-CFTR mRNA after caffeine
treatment did not result in the increase of the CFTR protein levels (Fig. 5-
B). In contrast, Ataluren induced also the increase of the CFTR protein
(Fig. 5-B). Interestingly, the combined treatment of caffeine and Ataluren
induced a significant increase of both CFTR mRNA and protein levels,
suggesting an additive effect of the two molecules (Figure 5 A-B).
To assess whether the full-length CFTR rescued protein was properly
localized to the plasmatic membrane, immunocytochemistry analysis
was performed using a CTFR antibody that recognizes the first external
loop of the channel. As positive control we used CFBE cells that express
the CFTR cDNA ectopically. The results show that the CTFR protein was
properly localized to the plasmatic membrane after the combined treat-
ment (Fig. 6).
4. Discussion
The readthrough approach could be an excellent method to restore
the expression of an mRNA harboring premature stop codon, however it
results in controversial response on the basis of the genetic contest. The
different response to Ataluren observed in different genetic diseases
could be attributed to several factors including the tissue physiology
(protein turnover, NDM functionality, etc.) or the minimum amount of
full-length protein required to perform its function. It is possible that in a
particular tissue/cell context a small amount of protein rescued by the
readthrough is sufficient to supply the complete absence of the mutated/
absent protein. In other tissue/cell, it could be necessary recover at least
the 50 % or more of the wild type protein.
Therefore, the approach based on the readthrough of the premature
stop codons remains a good strategy for recovering the full-length pro-
tein, but it may need some adjuvants. From this point of view it is crucial
the amount of the "target": the nonsense mutated mRNA. These mRNAs
are frequently eliminated by the nonsense-mediated mRNA decay
(NMD). By reducing the amount of PTC-containing mRNAs the NMD is
thought to act as a protective mechanism for the cell by reducing the
expression of truncated proteins that could potentially have deleterious,
dominant-negative functions. Reducing the pool of mRNAs available for
translation the NMD surveillance mechanism negatively impacts the
therapeutic suppression of PTCs. In order to perform the readthrough of
the premature stop codon it is of fundamental importance the presence of
a sufficient amount of mutatedmRNA and this is possible only if the NMD
pathway is attenuated, inhibited or shielded. On the basis of these ob-
servations, it is clear that the use of a drug (as caffeine) that induces
nonsense-mRNA stabilization could be a strategy to amplify the read-
through effect of Ataluren or others readthrough agents. Our results
showed that Ataluren induced, in light measure, the accumulation of a
little amount of nonsense-mRNA. The mechanism is not clear, we hy-
pothesize that Ataluren induces (in addition to the readthrough activity)
directly or indirectly this mRNA stability/accumulation. In a recent work
it was reported that molecules containing a central aromatic heterocycle
having two or three substituents including Ataluren could have multi-siteFig. 5. The combined treatment of caffeine and Ataluren
shows an additive effect on CFTR mRNA and protein
levels. A) Real-Time RT-PCR evaluation of CFTR mRNA
levels in IB3.1 cells untreated and treated for 24 hours
with: 0.75mM caffeine (Caff), 12 μМ Ataluren (PTC124),
and with a combination of the two (Caff/PTC124). B)
Western blot showing CFTR protein levels in IB3.1 cells
untreated (lane 1) or treated with the indicated mole-
cules (lane 2: 24h caffeine 0.75 mM; lane 3: 24h PTC124
12 μM; lane 4: 24h caffeine/24h PTC124. C) Histogram
of the densitometry of the Western blot bands. A primary
antibody raised against the C-terminus of CFTR was used
(see also Supplementary Fig.1 and 2).
Fig. 6. CFTR protein is localized to the cell membrane after the combined treatment of caffeine and Ataluren. Immunofluorescence assay showing the CFTR protein in
IB3.1 cells after 24h of treatment with caffeine, Ataluren (PTC124) and combined caffeine and PTC12. Nuclei were stained by DAPI (bleu), CFTR localization was
detected by a primary antibody that recognizes the first external loop of the protein (as secondary antibody, Alexa 488-green). Membrane and Golgi apparatus were
stained by WGA-Alexa 594 antibody.
L. Lentini et al. Heliyon 5 (2019) e01963binding to the protein synthesis machinery (Ng et al., 2018). In our
previous work we observed by molecular dynamic simulation that Ata-
luren binds near the CFTR-G542X-UGA stop codon in a 33 nucleotides
strand of CFTR mRNA (Lentini et al., 2014). These observations suggest
an interaction Ataluren/mRNA that might influence the mRNA
stability/accumulation.
Finally, our results indicate that the CFTR protein rescue is dependent
by the readthrough of the PTCs mediated by Ataluren and that this effect
increases when Ataluren disposes of a more abundant substrate (mRNA).
5. Conclusions
Our results show that the combined treatment of caffeine and Ata-
luren is able to enrich the target for the readthrough of the UGA pre-
mature stop codon, most probably by reducing the rate of CFTR mRNA
degradation, thus increasing the expression levels of CFTR protein
properly localized to the membrane of human IB3.1 cells. Our experi-
ments evidenced that the readthrough strategy to restore the translation
of full-length proteins could be a very good approach although it prob-
ably requires a further improvement in terms of nonsense-mRNAs target
recovery and could find application, besides CF, in several genetic dis-
eases due to nonsense mutations.5Declarations
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